Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVI-4065 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVI-4065 Injection | DRUG | - |
Inclusion Criteria: * Adult males 18 years to 64 years of age; * Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range) * Signed and dated written informed consent form; and * Willing to partici...
AVI-4065 is an investigational small molecule being developed for encephalitis, a neurological condition. It is currently in Phase 1 clinical development. The drug is being studied for its pharmacokinetic properties in the cerebral spinal fluid, with a completed trial involving healthy male volunteers.
AVI-4065 is being developed by Sarepta Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SRPT. The company is conducting clinical research on this investigational small molecule for the treatment of encephalitis.
AVI-4065 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A single Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
AVI-4065 has one completed clinical trial, identified as NCT00381433. This was a Phase 1 pharmacokinetic study of a single dose of AVI-4065 in cerebral spinal fluid, conducted in the United States with 12 healthy male volunteers aged 18 years and older.
AVI-4065 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT00381433, was a pharmacokinetic study, and the drug has not yet progressed to later-stage trials or received regulatory approval.